Through the application of IXICO’s data science expertise, these measurements have the potential to increase success-rates of clinical trials, reduce the cost of running them as well as reducing the burden on trial participants."
AI Technologies and approaches continue to develop at pace and have the potential to impact every stage of clinical development.
There are many definitions of AI but in essence, machine learning and AI specifically enable us to develop new analysis algorithms from ever increasing datasets and apply these to respond to new challenges. As such, it’s a huge field, and can be applied to solving a wide range of challenges. In neuroscience, AI has applications across the spectrum of understanding and treating the disease: from the very early stages of research in the selection of the most promising drug candidates, to clinical development programmes in interpreting complex patient data and even to supporting new models of care in the community.
IXICO have been harnessing machine learning and AI since our company’s inception in 2004. Our proprietary LEAP algorithm harnesses the power of large datasets and computer-based learning to segment specific regions of the brain and then accurately measure their volume. This provides a reliable method of measuring brain atrophy which can indicate progression of neurological disease. We have furthermore developed AI technology to assess brain pathology like white matter lesions and, more recently, to using data from wearable biosensors to accurately measure sleep patterns in Parkinson’s Disease and dementia patients. All these approaches allow us to understand disease symptoms more directly compared to manual assessment or complex in-clinic technology. Through applying IXICO’s data science expertise, these measurements have the potential to increase success-rates of clinical trials, reduce the cost of running them as well as reducing the burden on trial participants and their carers by reducing the need for clinic visits.
AI has the potential to complement our service offerings in multiple areas: we are actively working on technology to extend on the clinical endpoints that we can measure automatically from trial data. Besides imaging, we’re continuing to develop theses interpretive algorithms for new datatypes, such as from wearable biosensors, which is a rapidly developing field. Additionally, increasing data sizes collected at IXICO and advanced AI also have the potential to help us achieve greater efficiency in trial service delivery by enabling us to reliably automate processes such as image quality control and to develop predictive tools that can provide valuable insights to our customers on different aspects of trial performance.